Danaher Corporation announced its third‑quarter 2025 financial results on October 21, 2025, reporting sales of $6.053 billion, up 3.5 % year‑over‑year, and core revenue growth of 1.5 % year‑over‑year. Adjusted diluted net earnings per share were $1.27, surpassing analyst estimates. The company’s revenue mix reflected continued momentum in its bioprocessing business and stronger-than‑anticipated respiratory revenue at Cepheid.
CEO Rainer M. Blair highlighted that the company’s Danaher Business System (DBS) execution, combined with robust bioprocessing growth and better‑than‑expected Cepheid respiratory sales, enabled Danaher to exceed revenue, earnings, and cash‑flow expectations for the quarter. He emphasized the company’s focus on delivering value to customers, associates, and shareholders through breakthrough innovation and productivity gains across its businesses.
Danaher reaffirmed its full‑year 2025 outlook, maintaining guidance for core revenue growth of approximately 3 % and adjusted diluted net earnings per share of $7.70 to $7.80. The company underscored its commitment to investing in innovation, enhancing commercial execution, and driving meaningful productivity improvements across its portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.